CA-VELO3D
20.10.2020 15:02:11 CEST | Business Wire | Press release
VELO3D , an innovator in digital manufacturing, announced the expansion of its systems portfolio to include Sapphire XC, an “Extra Capacity” large-format printer that will increase production throughput by 5X and reduce cost-per-part by up to 75%, when compared to the existing Sapphire system.
The company also announced plans to roll-out Sapphire Gen 2, which will be a software and hardware upgrade to the current system. Users can expect an improvement of anywhere between 10-50% in productivity and part-cost metrics when compared to the current Sapphire system. The Sapphire Gen 2 upgrade will be available to retrofit on all installed systems starting in Q2 2021.
The Sapphire product family now includes Sapphire Gen 2, the 1-meter tall Sapphire 1MZ and Sapphire XC—all using the laser powder-bed fusion (LPBF) process with patented capabilities to print without consideration of support structures. Sapphire systems specifically address the aerospace, power generation, and energy markets' unmet needs for quality-assured manufacturing of uncompromised geometries.
"Printing larger parts without the additive manufacturing constraints of support structures is highly attractive to many industrial end-users,” said Benny Buller, founder, and CEO of VELO3D . “For the first time, customers will be able to 3D-print uncompromised geometries, with the highest confidence in part quality, in a large format system. Quality assurance with large scale components is critical because the economic impact of failed builds is very significant. We have demonstrated that our integrated solution is capable of producing a greater yield of high-quality parts, and that foundational technology will transfer to our new Sapphire XC."
Sapphire XC Features
- Larger build volume: Build volume 600mm x 550 mm (compared to 315mm x 400 mm in Sapphire)
- Higher productivity for production: 8 lasers x 1,000W each (compared to 2 lasers x 1,000W in Sapphire)
- Integrated manufacturing process: Fully integrated with Flow™ pre-print software and Assure™ quality control software
- Consistent architecture: Utilizes the same optical-train design, recoater technology, gas-flow technology, and metrology as the current Sapphire. Users can also expect similar material properties as Sapphire
- Qualified material alloys : Compatible alloys include Aluminum F357, Titanium 6AI-4V, INCONEL® 718 and HASTELLOY® X
Sapphire XC Pre-Order
Delivery of Sapphire XC will begin in Q4 2021. Early pre-order of Sapphire XC secures a price and an early manufacturing slot for the system. Existing orders of Sapphire XC will consume all available manufacturing slots for Q4 ’21 and most of Q1 ’22.
Webinar Invitation
To learn more about the value of the Sapphire XC large format system and how it addresses unmet customer needs, register for an informative online fireside chat on Oct 22nd at 10 a.m. Eastern Standard Time. Scott Dunham, Vice President of Research at Smartech Analysis will moderate a discussion with Benny Buller, founder and CEO of VELO3D . Live Q&A from the audience will be included in the webinar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005115/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
